Clene Swings to $3.92M Third-Quarter Net Income
CLNN sits 25% above its 52-week low of $3.015.
Summary
Clene reported third-quarter net income of $3.92 million, or 5 cents a share, on revenue of $56,000, a sharp reversal from the $13.4 million net loss it posted for Q2 2026, with the profit driven by warrant liability gains. The swing matters for a micro-cap that carried a going concern warning in its Q2 10-Q and has been funding itself through small registered direct offerings, including a $4 million raise at $3.28 a share in September. A profitable quarter, if it holds, eases the immediate cash pressure, though the company's cash runway extends only to mid-Q1 2027. The NDA for CNM-Au8 seeking accelerated approval was submitted to the FDA on October 19, and that review decision is the real driver from here, while Clene plans to initiate the Phase 3 RESTORE-ALS confirmatory trial of CNM-Au8 in ALS in 2Q of 2027.
At the time of this announcement, CLNN was trading at $3.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.6M. The 52-week trading range was $3.02 to $13.50. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.